CD38-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 


«12345678910111213...1415»
  • ||||||||||  Darzalex (daratumumab) / J&J
    Efficacy of anti-CD38 Treatment with Daratumumab in Two Cases of Refractory and Severe Sjogren Disease (Poster Hall; in person) -  Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4164;    
    Daratumumab may be an effective therapeutic strategy in severe and refractory Sjo patients, particularly when systemic manifestations are driven by pathogenic autoantibodies. Further studies are needed to assess the long-term efficacy and impact of daratumumab on autoreactive B cell repertoire and the room of daratumumab in the therapeutic arsenal of the disease.
  • ||||||||||  Elrexfio (elranatamab) / Pfizer
    The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Na (Trianti Upper Foyer; In Person) -  Sep 10, 2023 - Abstract #IMW2023IMW_760;    
    P2
    Further studies are needed to assess the long-term efficacy and impact of daratumumab on autoreactive B cell repertoire and the room of daratumumab in the therapeutic arsenal of the disease. Despite occasional early transient decreases, the results suggest that subcutaneous 76 mg QW elranatamab can improve the symptom and overall QOL of pts with RRMM, regardless of prior BCMA-targeted treatment.
  • ||||||||||  SINGLE CELL MULTI-OMIC CORRELATION OF SINGLE NUCLEOTIDE VARIANTS, COPY NUMBER VARIATION AND SURFACE EPITOPES FOR CLONAL PROFILING OF MYELOMA (Trianti Upper Foyer; In Person) -  Sep 10, 2023 - Abstract #IMW2023IMW_656;    
    This high-resolution, single cell assay offers a potential new modality for the diagnosis and surveillance of patients with suspected MGUS, SGUS or high-risk MM. We have demonstrated: 1) exceptional results from cryopreserved human specimens, 2) the ability to use genetic lesion profiling to positively identify subclonal MM and, most importantly, 3) correlate cell surface protein expression of potential therapeutic targets with each clonal and subclonal population.
  • ||||||||||  Blenrep (belantamab mafodotin-blmf) / GSK
    Real world outcomes of belantamab mafodotin from the UK and Ireland: updated results. (In Person) -  Sep 10, 2023 - Abstract #IMW2023IMW_595;    
    We report an ORR of 56% in our cohort of UK and Ireland patients receiving belamaf monotherapy under the NPP. We will present at the meeting extended follow-up results and an analysis across clinically relevant covariates to compare these outcomes with other studies of belamaf monotherapy.
  • ||||||||||  dexamethasone / Generic mfg.
    A single-center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM) (In Person) -  Sep 10, 2023 - Abstract #IMW2023IMW_553;    
    Whilst no significant differences were observed between specific treatment combinations in our RRMM population, there were notable trends toward improved response rates and TNTT in CD38/IMiD and IMiD/PI groups when compared to CD38/PI group. Further, no statistically significant response rate in doublet vs. triplet regimens was observed, raising the question of selecting truly synergistic drug combinations as well as optimal number of drugs in a treatment regimen for improved efficacy and decreased treatment related toxicity.
  • ||||||||||  SAR442257 / Sanofi
    Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma (In Person) -  Sep 10, 2023 - Abstract #IMW2023IMW_540;    
    Further, no statistically significant response rate in doublet vs. triplet regimens was observed, raising the question of selecting truly synergistic drug combinations as well as optimal number of drugs in a treatment regimen for improved efficacy and decreased treatment related toxicity. SAR442257 has increased binding capacity for RRMM due to CD38 and CD28 targets and demonstrated activity on RRMM cells as reasonable alternative for future RRMM therapy approach.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment (In Person) -  Sep 10, 2023 - Abstract #IMW2023IMW_506;    
    P1b/2, P2b
    In this cohort of heavily-pretreated pts with MM who received a selinexor regimen prior to NCA, overall survival was in the range of 1 year, akin to historical results seen with ADCs. The 8-week median time between administration of selinexor and NCAs suggests that selinexor, with various partner agents, did not negatively impact overall survival with subsequent NCA therapy
  • ||||||||||  Blenrep (belantamab mafodotin-blmf) / GSK
    Development of pERp1-ADC as a Novel Therapeutic for Multiple Myeloma (In Person) -  Sep 10, 2023 - Abstract #IMW2023IMW_496;    
    n/a In conclusion, we have found pERP1 to be highly expressed on the surface of MM cell lines in culture and of MM cells from patients in comparison with plasma cells from healthy donors, underscoring the potential of pERP1 as a novel immunotherapy target by using mAb or ADC.
  • ||||||||||  Novel Antibodies Identified by Phage Display Induce Direct Myeloma Cell Death (In Person) -  Sep 10, 2023 - Abstract #IMW2023IMW_473;    
    Our results show that phage display and NGS provide an innovative way to develop new antibodies with therapeutic potential for MM immunotherapy. Further characterization of the antibodies and investigations to identify the respective antigens are on-going.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Review, Journal:  Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature. (Pubmed Central) -  Sep 7, 2023   
    We used daratumumab combined with erythropoietin, which led to a dramatic response measured by stabilizing her hemoglobin levels and transfusion independence. Our case is the third reported case of refractory CAD successfully treated with daratumumab, which suggests that daratumumab might be a potential agent for the treatment and control of refractory Cold Agglutinin Disease.
  • ||||||||||  Tecvayli (teclistamab) / Genmab, J&J
    Long?Term Follow?Up From MajesTEC?1 of Teclistamab, a B?Cell Maturation Antigen (BCMA)  () -  Aug 31, 2023 - Abstract #SOHO2023SOHO_566;    
    P1, P2
    92% ORR in patients with advanced RRMM at RP2R and 83% ORR in patients with EMD (high-risk population with unmet need) support further evaluation. After ~2 years mFU, patients receiving teclistamab demonstrated deep and durable responses, supporting teclistamab as a safe and effective off-the-shelf BCMA bispecific therapy for patients with RRMM.
  • ||||||||||  Immunophenotyping of Chronic Lymphocytic Leukemia in Yemen. () -  Aug 14, 2023 - Abstract #IWCLL2023IWCLL_162;    
    The antigen expression patterns were in keeping with the WHO definition for CLL. However, there was higher expression of CD25 and CD11c, and half the cases in Yemen expressed CD38 antigen, known to be associated with a poorer prognosis.
  • ||||||||||  idasanutlin (RG7388) / Roche
    Journal, IO biomarker:  SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia. (Pubmed Central) -  Aug 2, 2023   
    The novel striking finding of this study was an independent link between SF3B1 mutational status and poor response to RG7388. Overall, SF3B1 mutations in CLL patient samples were associated with resistance to treatment with RG7388 ex vivo, and patients with the wild type for both SF3B1 and TP53 are more likely to benefit from treatment with MDM2 inhibitors.
  • ||||||||||  Review, Journal:  Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting. (Pubmed Central) -  Jul 29, 2023   
    Additionally, proteasome inhibitors such as bortezomib, ixazomib, and carfilzomib disrupt protein degradation, proving specifically toxic to cancerous plasma cells. Recent advancements also involve monoclonal antibodies targeting surface antigens, such as elotuzumab (anti-CS1) and daratumumab (anti-CD38), bispecific t-cell engagers such as teclistamab (anti-BCMA/CD3) and Chimeric antigen receptor T (CAR-T)-based strategies, with a growing focus on drugs that exhibit increasingly targeted action against neoplastic plasma cells and relevant effects on the tumor microenvironment.
  • ||||||||||  Talvey (talquetamab) / J&J
    Management Considerations for Dermatologic Toxicities Associated With Talquetamab, a GPRC5D (MC3) -  Jul 14, 2023 - Abstract #IMW2023IMW_19;    
    P1, P2
    Recent advancements also involve monoclonal antibodies targeting surface antigens, such as elotuzumab (anti-CS1) and daratumumab (anti-CD38), bispecific t-cell engagers such as teclistamab (anti-BCMA/CD3) and Chimeric antigen receptor T (CAR-T)-based strategies, with a growing focus on drugs that exhibit increasingly targeted action against neoplastic plasma cells and relevant effects on the tumor microenvironment. Management of dermatologic AEs included a heavy moisturizer for general dryness; ammonium lactate 12% lotion twice daily (BID) for hand and foot peeling; loratadine 10 mg oral tablet daily for 3
  • ||||||||||  Blenrep (belantamab mafodotin) / GSK
    Review, Journal:  Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. (Pubmed Central) -  Jun 10, 2023   
    Belantamab Mafodotin, a first-in-class anti-BCMA antibody-drug conjugate, demonstrated good efficacy and safety profile in triple-refractory patients in the phase 2 DREAMM-2 trial, and it was approved for the treatment of MM triple-exposed patients with >4 prior lines of therapy. Here, starting from Belantamab Mafodotin clinical trials and also exploring combination studies and different schedules in order to improve its efficacy and toxicity, we focused on real-life experiences all over the world, which have confirmed clinical trial data and encourage further Belantamab Mafodotin investigations.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Journal:  Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells. (Pubmed Central) -  May 24, 2023   
    Upon functionalizing the NK.NPs with an anti-CD38 antibody (Daratumumab), NK.NPs effectively targeted and eliminated CD38-positive patient-derived acute myeloid leukemia (AML) blasts ex vivo and were able to target and kill CD38-positive AML cells in vivo, in a disseminated AML xenograft system and reduced AML burden in the bone marrow compared to non-targeted, TRAIL-functionalized liposomes. Taken together, NK.NPs are able to mimicking key antitumorigenic functions of NK cells and warrant their development into nano-immunotherapeutic tools.
  • ||||||||||  Darzalex (daratumumab) / J&J, talquetamab (JNJ-64407564) / J&J
    TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS (festival hall) -  May 12, 2023 - Abstract #EHA2023EHA_2350;    
    P1b
    Steroid-sparing tal + dara showed deep and durable responses with promising mPFS in heavily pretreated pts with RRMM, including pts refractory to anti-CD38/BCMA and T-cell redirecting therapy, suggesting combined immunomodulatory actions can yield robust responses in pts with refractory disease. The safety profile was clinically manageable; no new signals were identified with longer follow-up.